spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  alemtuzumab 

 HSMN NewsFeed - 21 Jul 2016
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 7 Apr 2014
Genzyme to Resubmit Lemtrada(TM) Application for FDA Review
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Mar 2014
Genzyme’s Lemtrada(TM) Approved in Brazil for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 5 Mar 2014
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Dec 2013
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 19 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 13 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 4 Oct 2013
GSK and Genmab Announce European Submission to Regulatory Authorities for Arzerra(R) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Sep 2013
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 28 Jun 2013
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 17 May 2013
Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
Biopharmaceuticals Litigation
 HSMN NewsFeed - 25 Mar 2013
Arzerra Receives Approval in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Jan 2013
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 30 Aug 2012
Genmab Enters Worldwide Agreement With Janssen for Daratumumab
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 12 Jun 2012
Genzyme Submits Applications to FDA and EMA for Approval of LEMTRADA(TM) (alemtuzumab) for Multiple Sclerosis
Biopharmaceuticals Neurology FDA Regulatory
 HSMN NewsFeed - 27 Apr 2012
New Drug Application for Arzerra Submitted in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Jul 2011
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada(TM)*) in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Apr 2011
sanofi-aventis Completes Acquisition of Genzyme Corporation
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Feb 2011
sanofi-aventis to Acquire Genzyme for $74.00 in Cash Per Share Plus Contingent Value Right
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 31 Jan 2011
Genzyme Will Allow sanofi-aventis to Conduct Due Diligence
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Jan 2011
Genzyme Statement on Discussions with sanofi-aventis
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Nov 2010
Infinity Augments Executive Leadership Team, Appointing New Chief Medical Officer and New Vice President, Product Development and Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Oct 2010
Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 Aug 2010
Genzyme Confirms Receipt of Unsolicited Proposal
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 25 Mar 2010
Declaratory Relief Complaint for Patent Infringement Under Patent Based on Manufacture, Marketing and Sale of Arzerra
Biopharmaceuticals Oncology Litigation
 HSMN NewsFeed - 22 Jan 2010
Arzerra(TM) (Ofatumumab) Receives Positive Opinion for Conditional Approval in Europe for Refractory Chronic Lymphocytic Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Nov 2009
Alnara Pharmaceuticals Announces Appointment of Lee R. Brettman, M.D., FACP, to Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Feb 2009
GlaxoSmithKline and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Dec 2008
FDA Approves Genzyme's Mozobil
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Jul 2008
Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2007
FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Sep 2007
Updated REVLIMID(R) Clinical Results Presented at the 12th International Workshop on Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jun 2007
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 May 2007
Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Apr 2007
NCCN Updates Prevention and Treatment of Cancer-Related Infections Guidelines
Oncology
 HSMN NewsFeed - 27 Jul 2006
Genzyme Launches New Diagnostic Test for Common Blood Cancer
Diagnositcs Oncology
 HSMN NewsFeed - 21 Jun 2006
Celera Genomics Announces the Sale of Its Cathepsin S Inhibitor Program to Schering AG
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 3 Jun 2006
Genzyme and Berlex Oncology Announce Interim Results of Campath in First-Line Study of Chronic Lymphocytic Leukemia at ASCO
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 20

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 20 additional stories matching:
alemtuzumab
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.